Van Hoose Kyri K.'s Form 4 filing
Dermata Therapeutics, Inc. (DRMA) · filed Aug 18, 2026
- Accession no.
- 0001493152-26-039046
- Filed
- Aug 18, 2026, 5:21 PM ET
- Trade date
- Aug 16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Van Hoose Kyri K.CIK 0001860885 | Officer (SVP, CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +102,040 | –F2 | – | 232,463 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The purchase price per share of common stock and accompanying warrants was $1.47.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.